CHICAGO — Up to date survival knowledge from the randomized part 3 IMpower010 continued to assist adjuvant atezolizumab for sufferers with stage II to stage IIIA PD-L1-expressing non-small cell lung most cancers, in keeping with researchers.
A beforehand noticed DFS profit with atezolizumab (Tecentriq, Genentech) — an anti-PD-L1 antibody — has translated into favorable OS outcomes for sure sufferers, findings offered at ASCO Annual Assembly confirmed.
Background and strategies
The IMpower010 trial included sufferers with stage IB to stage IIIA NSCLC who had ECOG efficiency standing of 0 or 1.
All 1,005 sufferers within the intention-to-treat inhabitants underwent full resection 4 to 12 weeks prior to check enrollment, adopted by one to 4 cycles of cisplatin plus pemetrexed, gemcitabine, docetaxel or vinorelbine.
After chemotherapy, researchers randomly assigned 507 sufferers to 1,200 mg atezolizumab each 3 weeks for 16 cycles. The opposite 498 acquired finest supportive care.
Investigator-assessed DFS served because the research’s main endpoint.
Researchers assessed DFS hierarchically, beginning with sufferers with stage II to stage IIIA illness who had PD-L1 tumor expression on at the least 1% of tumor cells, adopted by all sufferers with stage II to stage IIIA illness randomly assigned to remedy, adopted by the intention-to-treat inhabitants.
OS served as a secondary endpoint however solely may very well be formally examined when the statistical significance boundary for DFS had been crossed in all three designated populations.
Earlier outcomes
An interim evaluation — carried out after knowledge cutoff in January 2021 — confirmed improved DFS with atezolizumab amongst all sufferers with stage II to stage IIIA illness (stratified HR = 0.79; 95% CI, 0.64-0.96), these with stage II to stage IIIA illness with PD-L1 expression ( 1% of tumor cells, stratified HR = 0.66; 95% CI, 0.5-0.88; 50% of tumor cells, unstratified HR = 0.43; 95% CI, 0.27-0.68).
The primary OS interim evaluation — carried out after knowledge cutoff in April 2022 — confirmed a pattern towards improved OS in favor of atezolizumab amongst these with stage II to stage IIIA and PD-L1 expression (( 1% of tumor cells, stratified HR = 0.71; 95% CI, 0.49-1.03; 50% of tumor cells, unstratified HR = 0.43; 95% CI, 0.24-0.78).
Up to date outcomes
At ASCO, Heather L. Wakelee, MD, professor of drugs at Stanford College, offered up to date outcomes from a remaining DFS evaluation and a second OS interim evaluation.
After minimal follow-up of 60 months, greater than half of sufferers within the intention-to-treat inhabitants remained on research (59.4% for atezolizumab vs. 56.6% for finest supportive care).
The distinction in DFS and OS with atezolizumab didn’t attain statistical significance within the intention-to-treat inhabitants (stratified HR = 0.85; 95% CI, 0.71-1.01), or amongst all sufferers with stage II to stage III illness randomly assigned to remedy (stratified HR = 0.83; 95% CI, 0.69-1).
Atezolizumab conferred a major DFS profit amongst sufferers with stage II to stage IIIA illness who had PD-L1 expression on at the least 1% of tumor cells (median, 68.5 months vs. 37.3 months; stratified HR = 0.7; 95% CI, 0.55-0.91). On this subgroup, a better proportion of atezolizumab-treated sufferers remained illness free at 3 years (62.7% vs. 52.1%) and 5 years (53.2% vs. 42.7%).
Outcomes confirmed a numerical enchancment in OS on this subgroup (median, not estimable vs. 87.1 months; stratified HR = 0.77; 95% CI, 0.56-1.06), with increased charges of 3-year OS (82.1% vs. 78.9%) and 5-year OS (74.8% vs. 66.3%).
The profit with atezolizumab appeared notably sturdy amongst sufferers with stage II to stage IIIA illness who had PD-L1 expression on at the least 50% of tumor cells. On this group, atezolizumab-treated sufferers achieved longer median DFS (not estimable vs. 41.1 months; unstratified HR = 0.48; 95% CI, 0.32-0.72). The next proportion remained illness free at 3 years (74.9% vs. 53.2%) and 5 years (65.1% vs. 44.5%).
OS outcomes additionally favored atezolizumab on this subgroup (median, not estimable vs. 87.1 months; unstratified HR = 0.47; 95% CI, 0.28-0.77), with increased charges of 3-year OS (89.1% vs. 77.8%) and 5-year OS (82.7% vs. 65.3%).
Security analyses confirmed 9 sufferers (1.8%) assigned atezolizumab and three (0.6%) assigned finest supportive care died as a consequence of adversarial occasions.
General, atezolizumab exhibited a security profile in line with prior analyses. Researchers noticed no new or sudden security indicators.
Perspective
Robert Chun-Hao Hsu, MD
These outcomes are a continuation of what we noticed from the earlier interim evaluation. There clearly is a profit for sufferers who’ve a PD-L1 tumor proportion rating larger than 50%. There appears to be modest enchancment for these with PD-L1 tumor proportion scores of 1% to 49%, however there doesn’t appear to be a profit for sufferers with scores lower than 1%.
Now that we’ve knowledge from a number of research of neoadjuvant or perioperative immunotherapy, the main target going ahead can be attempting to find out which sufferers could profit from adjuvant immunotherapy. I additionally surprise if utilizing PD-L1 rating is a ample marker to make that call, or whether or not we will use technologic advances to determine different biomarkers.
Regardless of the elevated emphasis on neoadjuvant or perioperative remedy, we do nonetheless have sufferers who endure upfront resection, both as a consequence of upstaging of illness or affected person choice. Consequently, there may be nonetheless a job for adjuvant-only immunotherapy, so that is essential info for us as clinicians to have to assist make choices about what to do within the adjuvant setting for sufferers who don’t get neoadjuvant immunotherapy.
Robert Chun-Hao Hsu, MD
Keck Drugs of USC
Disclosures: Hsu reviews honoraria from DAVA Oncology/Dedham Group, in addition to consulting roles with Focused Oncology and Takeda.
Sources/Disclosures
Collapse
Wakelee HA, et al. Summary LBA8035. Introduced at: ASCO Annual Assembly; Could 31-June 4, 2024; Chicago.
Disclosures:
F. Hoffmann-La Roche Ltd. sponsored this research. Wakelee reviews consulting charges from IO Biotech and Mirati Therapeutics; unpaid advisory roles with AstraZeneca, Bristol Myers Squibb, Genentech/Roche and Merck; and analysis funding to her establishment from AstraZeneca, Bayer, Bristol Myers Squibb, Genentech/Roche, Helsinn Therapeutics, Merck, Seagen and Xcovery. Please see the summary for all different researchers’ related monetary disclosures.
